-+ 0.00%
-+ 0.00%
-+ 0.00%

GRAIL To Reveal New Data From NHS-Galleri And PATHFINDER 2 At 2026 ASCO Annual Meeting

Benzinga·04/21/2026 20:55:48
Listen to the news

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29-June 2, 2026.